Eikon Therapeutics, Inc. Common Stock (EIKN) vs Enanta Pharmaceuticals, Inc. (ENTA)
A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and Enanta Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EIKN
Eikon Therapeutics, Inc. Common Stock
$7.56HealthcareDelayed quote: Oct 6, 2026, 9:39 AM EDT
ENTA
Enanta Pharmaceuticals, Inc.
$12.59HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
Total return — EIKN vs ENTA
growth of $100 · dividends reinvested · last 1yEIKN -49.7% (-49.7%/yr)ENTA -4.5% (-4.5%/yr)ENTA compounded faster over this window
EIKN ENTA
EIKN vs ENTA: by the numbers
- •EIKN is the larger company ($409M vs $366M market cap).
- •Both run net losses; EIKN's is the smaller (0.00% vs -96.89% net margin).
Metrics side by side
Valuation
| Metric | EIKN | ENTA |
|---|---|---|
| P/S ratio | N/A | 5.61 |
| P/B ratio | 0.88 | 3.62 |
Profitability
| Metric | EIKN | ENTA |
|---|---|---|
| Gross margin | 0.00% | 98.15% |
| Operating margin | 0.00% | -130.65% |
| Net margin | 0.00% | -96.89% |
| ROE | -69.06% | -62.56% |
| ROIC | -46.16% | -24.20% |
Growth (annualized)
| Metric | EIKN | ENTA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -7.65% |
| Total return CAGR (5Y) | N/A | -26.94% |
Go deeper
Dig into the metrics
Eikon Therapeutics, Inc. Common Stock ROEEnanta Pharmaceuticals ROEEikon Therapeutics, Inc. Common Stock operating marginEnanta Pharmaceuticals operating marginEikon Therapeutics, Inc. Common Stock revenue growthEnanta Pharmaceuticals revenue growthEikon Therapeutics, Inc. Common Stock free cash flowEnanta Pharmaceuticals free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.